EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Interleukin-31: A Pro-inflammatory Oriented Cytokine

Giuseppe Murdaca, Francesca Paladin, Andrea Orsi, Sebastiano Gangemi

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl37462 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Giuseppe Murdaca und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Genova, Viale Benedetto XV, 16132 Genova, Italy. Hauptthemen laut MEDLINE: Interleukins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 immunity is represented by T helper 2 (Th2) lymphocytes and the cytokines produced downstream (Interleukin (IL)-4, IL-13, IL-31). They are increasingly recognized as pivotal mediators in the pathogenesis of immune-mediated dermatological conditions such as atopic dermatitis (AD) and psoriasis (Pso). In these disorders, they initiate and amplify immunological signaling cascades, promote cutaneous inflammation, and contribute to the induction of pruritus. In this context, IL-33 and IL-31 would be believed to be intrinsically linked and related to the acuity of the disease. The presence of an interleukin could in fact trigger the other, amplifying the inflammatory process of itchy skin disorders and therefore the extent of the symptoms. High levels of IL-31 may support the maintenance of a microenvironment that promotes both the growth and spread of solid tumors, as well as the development of cancer-associated pruritus. Given these premises, non-histaminergic mediators such as IL-31 and IL-33 could be explored as novel therapeutic targets for the treatment of pruritus in immune-mediated skin diseases and cancer, improving the QoL of patients. Finally, we briefly discussed the recent innovations in the field of monoclonal anti-IL-31 therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InterleukinsHumansPruritusDermatitis, AtopicAnimalsInterleukin-33InflammationNeoplasmsPsoriasis

Stichwörter der Autor:innen

IL-31IL-31 receptorsIL-33IL-33/IL-31 axiscancer

Substanzen

InterleukinsIL31 protein, humanInterleukin-33

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Genova, Viale Benedetto XV, 16132 Genova, Italy.
  • Allergology and Clinical Immunology Unit, San Bartolomeo Hospital, 19038 Sarzana, Italy.
  • Elderly and Disabeld Department, San Paolo Hospital, 17100 Savona, Italy.
  • Department of Health Sciences (DISSAL), University of Genova, 16132 Genova, Italy.
  • Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, 16132 Genova, Italy.
  • Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.

Zitieren

APA

Murdaca, G., Paladin, F., Orsi, A., & Gangemi, S. (2025). Interleukin-31: A Pro-inflammatory Oriented Cytokine. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl37462

Vancouver

Murdaca G, Paladin F, Orsi A, Gangemi S. Interleukin-31: A Pro-inflammatory Oriented Cytokine. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl37462

BibTeX
@article{Murdaca2025,
  author = {Murdaca, Giuseppe and Paladin, Francesca and Orsi, Andrea and Gangemi, Sebastiano},
  title = {Interleukin-31: A Pro-inflammatory Oriented Cytokine},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl37462}
}
Kostenlos starten →